Iradimed Co Stock Z Score
IRMD Stock | USD 43.85 1.85 4.40% |
Iradimed | Z Score |
Iradimed Co Company Z Score Analysis
Iradimed's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Iradimed Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Iradimed is extremely important. It helps to project a fair market value of Iradimed Stock properly, considering its historical fundamentals such as Z Score. Since Iradimed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Iradimed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Iradimed's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
According to the company's disclosures, Iradimed Co has a Z Score of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Iradimed Current Valuation Drivers
We derive many important indicators used in calculating different scores of Iradimed from analyzing Iradimed's financial statements. These drivers represent accounts that assess Iradimed's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Iradimed's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 263.8M | 276.4M | 570.5M | 355.4M | 598.3M | 628.2M | |
Enterprise Value | 223.3M | 229.1M | 511.0M | 299.6M | 550.5M | 578.1M |
Iradimed Institutional Holders
Institutional Holdings refers to the ownership stake in Iradimed that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Iradimed's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Iradimed's value.Shares | Geode Capital Management, Llc | 2023-12-31 | 158.2 K | State Street Corporation | 2023-12-31 | 149.7 K | Goldman Sachs Group Inc | 2023-12-31 | 108.2 K | Resource Consulting Group Inc | 2023-12-31 | 103 K | Millennium Management Llc | 2023-12-31 | 102.8 K | Hillsdale Investment Management Inc. | 2023-12-31 | 89.7 K | Northern Trust Corp | 2023-12-31 | 85.6 K | Rice Hall James & Associates, Llc | 2023-12-31 | 76.9 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 72.6 K | Nine Ten Capital Management Llc | 2023-12-31 | 799.4 K | Blackrock Inc | 2023-12-31 | 651.9 K |
Iradimed Fundamentals
Return On Equity | 0.24 | ||||
Return On Asset | 0.14 | ||||
Profit Margin | 0.26 % | ||||
Operating Margin | 0.30 % | ||||
Current Valuation | 484.12 M | ||||
Shares Outstanding | 12.64 M | ||||
Shares Owned By Insiders | 37.03 % | ||||
Shares Owned By Institutions | 55.05 % | ||||
Number Of Shares Shorted | 104.88 K | ||||
Price To Earning | 28.70 X | ||||
Price To Book | 7.30 X | ||||
Price To Sales | 7.98 X | ||||
Revenue | 65.56 M | ||||
Gross Profit | 41.28 M | ||||
EBITDA | 20.04 M | ||||
Net Income | 17.19 M | ||||
Cash And Equivalents | 55.59 M | ||||
Cash Per Share | 4.42 X | ||||
Total Debt | 2.04 M | ||||
Debt To Equity | 0.03 % | ||||
Current Ratio | 12.83 X | ||||
Book Value Per Share | 5.64 X | ||||
Cash Flow From Operations | 13.47 M | ||||
Short Ratio | 2.35 X | ||||
Earnings Per Share | 1.35 X | ||||
Price To Earnings To Growth | 4.46 X | ||||
Target Price | 62.5 | ||||
Number Of Employees | 148 | ||||
Beta | 0.86 | ||||
Market Capitalization | 538.52 M | ||||
Total Asset | 92.16 M | ||||
Retained Earnings | 43.26 M | ||||
Working Capital | 59.67 M | ||||
Current Asset | 33.95 M | ||||
Current Liabilities | 2.89 M | ||||
Annual Yield | 0 % | ||||
Net Asset | 92.16 M | ||||
Last Dividend Paid | 0.15 |
About Iradimed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iradimed Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iradimed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iradimed Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Iradimed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Iradimed's short interest history, or implied volatility extrapolated from Iradimed options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Iradimed Piotroski F Score and Iradimed Valuation analysis. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Iradimed Stock analysis
When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Iradimed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.231 | Dividend Share 0.15 | Earnings Share 1.35 | Revenue Per Share 5.202 | Quarterly Revenue Growth 0.174 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.